Overview

• Researchers analyzed data from four clinical trials involving 4,677 obese adults, including 2,999 women and 1,678 men.
• Women lost up to 24.6% of their body weight on tirzepatide, compared to 18.1% for men.
• The trials, funded by Eli Lilly, tested tirzepatide against a placebo over a period of 72 to 88 weeks.
• While the safety profile was similar for both sexes, women reported higher rates of nausea and vomiting.
• Further research is needed to understand why women experience greater weight reduction on tirzepatide.